INSTIs | p Value | |||
---|---|---|---|---|
Raltegravir(n=223) | Elvitegravir(n=159) | Dolutegravir(n=351) | ||
Patients switching from INSTI (n=133) | 66 (29.6%) | 40 (25.2%) | 27 (7.7%) | <0.001 |
Reasons for switching | ||||
Schedule optimisation 70 (52.6%) | 42 (18.3%) | 28 (17.6%) | 5 (1.4%) | <0.001 |
Drug–drug interactions 3 (2.3%) | 0 (0%) | 3 (1.9%) | 0 (0%) | <0.001 |
Pregnancy 2 (1.5%) | 0 (0%) | 0 (0%) | 2 (0.6%) | <0.001 |
LV 18 (13.5%) | 16 (7.2%) | 2 (1.3%) | 0 (0%) | <0.001 |
Adverse events 40 (30.1%) Neuropsychiatrics Dermatologic Gastrointestinal Others | 8 (3.6%) 3 (1.3%) 0 (0%) 1 ( 0.4%) 4 (2.2%) | 7 (4.4%) 1 (0.6%) 0 (0%) 2 (1.3%) 4 (2.5%) | 20 (5.7%) 9 (2.6%) 5 (1.4%) 12 (3.4%) 3 (0.9%) | <0.001 0.002 0.001 <0.001 <0.001 |